| Insideraktier | 5 551 shares |
| Totalt antal insynspersoner | 25 |
Insider Sentiment Score
Insider sentiment score hittar de företag som köps av foretagsinsynspersoner.
Det är resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av insiderackumulation. Poängmodellen använder en kombination av nettoantalet insiders som köpt de föregående 90 dagarna, det totala antalet aktier som köpts i procent av aktiekapitalet och det totala antalet aktier som ägs av insiders. Siffran sträcker sig från 0 till 100, med högre siffror som indikerar en högre nivå av ackumulering för sina kamrater, och 50 är genomsnittet.
Uppdateringsfrekvens: Dagligen
Se Insiders Top Picks, som ger en lista över företag med högsta insiderackumulation.
Office Sentiment Score
Officersentiment Score hittar företag som köps av Corporate Officers.
Per definition Corporate Officers är Corporate Insiders, men till skillnad från vissa av de andra Insiders (10 % aktieägare och styrelseledamöter), arbetar ämbetsmän för företaget dagligen och de använder sina egna pengar när de handlar . (10 % aktieägare och styrelseledamöter är ofta fondförvaltare som förvaltar andras pengar.) Som sådan är insideraffärer som görs av tjänstemän mycket mer betydelsefulla och bör behandlas på lämpligt sätt.
Liksom Insider Sentiment Score är Officer Sentiment Score resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av officersackumulering.
Uppdateringsfrekvens: Dagligen
Se insiderns bästa val, vilket ger en lista över företag med högsta insider sentiment.
Viktiga insidernyckeltal
Denna kort visar hur företaget rankas längs olika insidernyckeltal. Procenttilrankningen visar hur detta företag jämförs med andra företag på USA-marknaden. Högre rankingar indikerar bättre situationer.
Till exempel anses det allmänt att insiderköp är en positiv indikator, så företag med mer insiderköp skulle rankas högre än företag med mindre insiderköp (eller til och med insiderförsäljning).
Procent av flytande köpta av insiders (ranking)
0.000 %( )
6048 out of 11220Procentandelen av aktier köpta av insiders är det totala antalet aktier som köpts av insiders minus det totala antalet aktier som sålts av insiders under de senaste 90 dagarna, dividerat med det totala antalet aktier och multiplicerat med 100.
Insiderhandelsdiagram
BlackRock Health Sciences Trust insideraffärer visas i följande diagram. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. I allmänhet är det i allmänhet olagligt för insiders att göra affärer i sina företag baserat på väsentlig, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4.
Insiderlista och lönsamhetsstatistik
Den här tabellen visar listan över kända insiders och genereras automatiskt från anmälningar som avslöjas till SEC. Förutom namnen, den senaste titeln och direktören, tjänstemannen eller ägarbeteckningen på 10 %, tillhandahåller vi de senaste avslöjade innehaven. Dessutom, när det är möjligt tillhandahåller vi insiderns historiska handelsresultat. Det historiska handelsresultatet är ett vägt genomsnitt av resultatet för faktiska köptransaktioner på den öppna marknaden som insidern gjort. För mer information om hur detta beräknas, titta på detta YouTube-webinarium.
See our leaderboard of most profitable insider traders.
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
| Christopher Accettella - | 821 | 821 | |
| Janey Ahn | 0 | ||
| Richard Cavanagh | 1 691 | ||
| Michael J Castellano Director - [D] | 400 | 400 | |
| Robert Crothers | 0 | ||
| Jonathan Diorio | 0 | ||
| Cynthia Egan Director - [D] | 3 737 | 3 737 | |
| Frank Fabozzi | 142 |
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
| Kathleen F Feldstein | 484 | ||
| James T Flynn | 882 | ||
| Robert W Fairbairn | 0 | ||
| Henry Gabbay Director - [D] | 0 | 0 | |
| Robert Glenn Hubbard | 2 941 | ||
| Jerrold B Harris | 2 373 | ||
| W Carl Kester | 1 343 | ||
| Jeffrey Gene Lee - | 0 | 0 |
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
| Xiang Liu - | 0 | 0 | |
| Lynch Catherine A. | 474 | ||
| Kyle McClements - | 593 | 593 | |
| Barbara Novick | 0 | ||
| Charles Park | 0 | ||
| John F Powers | 0 | ||
| Karen P Robards | 619 | ||
| Trent Walker | 0 | ||
| H Erin Xie - | 0 | 0 |
Report errors via our new Insider Auditing Tool
Track Records av insiderköp - Kortsiktig vinstanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i BME / BlackRock Health Sciences Trust. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste köpen på öppna marknaden som inte var en del av en automatisk handelsplan.
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Track Records av insiderförsäljning - Kortsiktig förlustanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i BME / BlackRock Health Sciences Trust. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste försäljningarna på öppna marknaden som inte var en del av en automatisk handelsplan.
| Handelsdatum | Insider | Rapporterade aktier |
Rapporterat pris |
Justerade aktier |
Justerat pris |
Kostnadsbasis | Dagar til Min |
Pris vid Min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-12-09 | GABBAY HENRY | 650 | 42,1916 | 650 | 42,1916 | 27 425 | 293 | 36.5692 | −3 654 | −13,32 |
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Transaktionshistorik
Klicka på länkikonen för att se hela transaktionshistoriken. Transaktioner som rapporteras som en del av en automatisk handelsplan 10b5-1 kommer att ha ett X i kolumnen markerad 10b-5.
| Fil datum |
Handel datum |
Schema | Insider | Ticker | Värdepappertitel | Kod | Direkta | Utövningspris | Enhet pris |
Enheter ändrad |
Värde ändrad (1K) |
Kvarvarande Optioner |
Kvarvarande Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-04 | 2025-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 40,9200 | −13 471 | −551 | 0 | ||||
| 2025-02-04 | 2025-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 13 471 | 13 471 | ||||||
| 2025-02-04 | 2025-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 40,9200 | −281 | −11 | 0 | ||||
| 2025-02-04 | 2025-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 281 | 281 | ||||||
| 2025-02-04 | 2025-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 40,9200 | −202 | −8 | 821 | ||||
| 2025-02-04 | 2025-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 202 | 1 023 | ||||||
| 2025-02-04 | 2025-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 40,9200 | −641 | −26 | 593 | ||||
| 2025-02-04 | 2025-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 641 | 1 234 | ||||||
| 2024-02-02 | 2024-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 41,4800 | −626 | −26 | 2 736 | ||||
| 2024-02-02 | 2024-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 626 | 3 361 | ||||||
| 2024-02-02 | 2024-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 41,4800 | −14 947 | −620 | 0 | ||||
| 2024-02-02 | 2024-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 14 947 | 14 947 | ||||||
| 2024-02-02 | 2024-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 41,4800 | −203 | −8 | 770 | ||||
| 2024-02-02 | 2024-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 203 | 972 | ||||||
| 2024-02-02 | 2024-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 41,4800 | −189 | −8 | 0 | ||||
| 2024-02-02 | 2024-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 189 | 189 | ||||||
| 2023-02-02 | 2023-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 43,5600 | −96 | −4 | 0 | ||||
| 2023-02-02 | 2023-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 96 | 96 | ||||||
| 2023-02-02 | 2023-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 43,5600 | −616 | −27 | 522 | ||||
| 2023-02-02 | 2023-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 616 | 1 138 | ||||||
| 2023-02-02 | 2023-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 43,5600 | −13 967 | −608 | 0 | ||||
| 2023-02-02 | 2023-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 13 967 | 13 967 | ||||||
| 2023-02-02 | 2023-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 43,5600 | −206 | −9 | 722 | ||||
| 2023-02-02 | 2023-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 206 | 928 | ||||||
| 2023-02-02 | 2023-01-31 | 4 | Lee Jeffrey Gene | BME | Common Stock | D | 43,5600 | −205 | −9 | 0 | ||||
| 2023-02-02 | 2023-01-31 | 4 | Lee Jeffrey Gene | BME | Common Stock | D | 205 | 205 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | −287 | 0 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | −144 | 144 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | −201 | 401 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | 45,1000 | 707 | 32 | 707 | ||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 45,1000 | −632 | −29 | 494 | ||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 632 | 1 126 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | −78 | 0 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | −64 | 64 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | −61 | 123 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | 45,1000 | 208 | 9 | 208 | ||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 45,1000 | −203 | −9 | 684 | ||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 203 | 887 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Lee Jeffrey Gene | BME | Phantom Shares | D | −71 | 143 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Lee Jeffrey Gene | BME | Phantom Shares | D | 45,1000 | 364 | 16 | 364 | ||||
| 2022-02-02 | 2022-01-31 | 4 | Lee Jeffrey Gene | BME | Common Stock | D | 45,1000 | −71 | −3 | 0 | ||||
| 2022-02-02 | 2022-01-31 | 4 | Lee Jeffrey Gene | BME | Common Stock | D | 71 | 71 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | −7 518 | 0 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | −3 739 | 3 739 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | −4 359 | 8 719 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | 45,1000 | 15 174 | 684 | 15 174 | ||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 45,1000 | −15 617 | −704 | 0 | ||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 15 617 | 15 617 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Liu Xiang | BME | Phantom Shares | D | 45,1000 | 272 | 12 | 272 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Phantom Shares | D | −93 | 0 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Phantom Shares | D | −74 | 74 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Phantom Shares | D | −60 | 121 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Phantom Shares | D | 47,8800 | 175 | 8 | 175 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Common Stock | D | 47,8800 | −228 | −11 | 649 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Common Stock | D | 228 | 877 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Phantom Shares | D | −366 | 0 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Phantom Shares | D | −273 | 273 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Phantom Shares | D | −137 | 274 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Phantom Shares | D | 47,8800 | 572 | 27 | 572 | ||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Common Stock | D | 47,8800 | −776 | −37 | 469 | ||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Common Stock | D | 776 | 1 245 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Lee Jeffrey Gene | BME | Phantom Shares | D | 47,8800 | 204 | 10 | 204 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Phantom Shares | D | −3 172 | 0 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Phantom Shares | D | −7 143 | 7 143 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Phantom Shares | D | −3 553 | 7 105 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Phantom Shares | D | 47,8800 | 12 425 | 595 | 12 425 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Common Stock | D | 47,8800 | −13 867 | −664 | 0 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Common Stock | D | 13 867 | 13 867 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | −346 | 346 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | −258 | 516 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | 41,1200 | 393 | 16 | 393 | ||||
| 2020-02-04 | 2020-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 41,1200 | −604 | −25 | 443 | ||||
| 2020-02-04 | 2020-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 604 | 1 047 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | −1 641 | 0 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | −2 998 | 2 998 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | −6 752 | 13 503 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | 41,1200 | 10 178 | 419 | 10 178 | ||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 41,1200 | −11 391 | −468 | 0 | ||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 11 391 | 11 391 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | −88 | 88 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | −70 | 140 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | 41,1200 | 173 | 7 | 173 | ||||
| 2020-02-04 | 2020-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 41,1200 | −158 | −7 | 610 | ||||
| 2020-02-04 | 2020-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 158 | 769 | ||||||
| 2019-07-02 | 2019-06-28 | 4 | Egan Cynthia | BME | Common Stock | D | 38,9200 | 3 737 | 145 | 3 737 | ||||
| 2019-02-04 | 2019-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | −1 544 | 1 544 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | −2 820 | 5 640 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | 39,6700 | 19 052 | 756 | 19 052 | ||||
| 2019-02-04 | 2019-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 39,6700 | −4 364 | −173 | 0 | ||||
| 2019-02-04 | 2019-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 4 364 | 4 364 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | −325 | 651 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | 39,6700 | 728 | 29 | 728 | ||||
| 2019-02-04 | 2019-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 39,6700 | −325 | −13 | 417 | ||||
| 2019-02-04 | 2019-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 325 | 742 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | −83 | 166 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | 39,6700 | 198 | 8 | 198 | ||||
| 2019-02-04 | 2019-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 39,6700 | −83 | −3 | 577 | ||||
| 2019-02-04 | 2019-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 83 | 660 | ||||||
| 2018-10-17 | 2018-10-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 41,2500 | 32 | 1 | 1 343 | ||||
| 2018-10-17 | 2018-10-15 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 41,2500 | 50 | 2 | 474 | ||||
| 2018-10-17 | 2018-10-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 41,2500 | 17 | 1 | 619 | ||||
| 2018-10-17 | 2018-10-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 41,2500 | 75 | 3 | 1 783 | ||||
| 2018-10-17 | 2018-10-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 41,2500 | 109 | 5 | 1 691 | ||||
| 2018-10-17 | 2018-10-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 41,2500 | 125 | 5 | 2 941 | ||||
| 2018-07-17 | 2018-07-13 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 41,1700 | 126 | 5 | 2 773 | ||||
| 2018-07-17 | 2018-07-13 | 4 | KESTER W CARL | BME | Performance Rights | D | 41,1700 | 32 | 1 | 1 291 | ||||
| 2018-07-17 | 2018-07-13 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 41,1700 | 50 | 2 | 418 | ||||
| 2018-07-17 | 2018-07-13 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 41,1700 | 17 | 1 | 593 | ||||
| 2018-07-17 | 2018-07-13 | 4 | Castellano Michael J | BME | Performance Rights | D | 41,1700 | 75 | 3 | 1 682 | ||||
| 2018-07-17 | 2018-07-13 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 41,1700 | 109 | 5 | 1 557 | ||||
| 2018-04-17 | 2018-04-13 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 34,5200 | 59 | 2 | 362 | ||||
| 2018-04-17 | 2018-04-13 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 34,5200 | 20 | 1 | 567 | ||||
| 2018-04-17 | 2018-04-13 | 4 | Castellano Michael J | BME | Performance Rights | D | 34,5200 | 89 | 3 | 1 581 | ||||
| 2018-04-17 | 2018-04-13 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 34,5200 | 130 | 5 | 1 424 | ||||
| 2018-04-17 | 2018-04-13 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 34,5200 | 150 | 5 | 2 604 | ||||
| 2018-04-17 | 2018-04-13 | 4 | KESTER W CARL | BME | Performance Rights | D | 34,5200 | 38 | 1 | 1 238 | ||||
| 2018-02-02 | 2018-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | 36,2100 | 916 | 33 | 916 | ||||
| 2018-02-02 | 2018-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | 36,2100 | 234 | 8 | 234 | ||||
| 2018-02-02 | 2018-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | −1 450 | 2 899 | ||||||
| 2018-02-02 | 2018-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | 36,2100 | 7 946 | 288 | 7 946 | ||||
| 2018-02-02 | 2018-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 36,2100 | −1 450 | −52 | 0 | ||||
| 2018-02-02 | 2018-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 1 450 | 1 450 | ||||||
| 2018-01-17 | 2018-01-12 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 36,5900 | 56 | 2 | 298 | ||||
| 2018-01-17 | 2018-01-12 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 36,5900 | 19 | 1 | 538 | ||||
| 2018-01-17 | 2018-01-12 | 4 | Castellano Michael J | BME | Performance Rights | D | 36,5900 | 84 | 3 | 1 467 | ||||
| 2018-01-17 | 2018-01-12 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 36,5900 | 123 | 5 | 1 272 | ||||
| 2018-01-17 | 2018-01-12 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 36,5900 | 141 | 5 | 2 413 | ||||
| 2018-01-17 | 2018-01-12 | 4 | KESTER W CARL | BME | Performance Rights | D | 36,5900 | 36 | 1 | 1 179 | ||||
| 2017-10-17 | 2017-10-13 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 36,7000 | 93 | 3 | 1 130 | ||||
| 2017-10-17 | 2017-10-13 | 4 | Harris Jerrold B | BME | Performance Rights | D | 36,7000 | 152 | 6 | 2 373 | ||||
| 2017-10-17 | 2017-10-13 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 36,7000 | 141 | 5 | 2 234 | ||||
| 2017-10-17 | 2017-10-13 | 4 | KESTER W CARL | BME | Performance Rights | D | 36,7000 | 36 | 1 | 1 124 | ||||
| 2017-10-17 | 2017-10-13 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 36,7000 | 56 | 2 | 238 | ||||
| 2017-10-17 | 2017-10-13 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 36,7000 | 37 | 1 | 510 | ||||
| 2017-10-17 | 2017-10-13 | 4 | Castellano Michael J | BME | Performance Rights | D | 36,7000 | 84 | 3 | 1 360 | ||||
| 2017-07-18 | 2017-07-14 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 37,1900 | 55 | 2 | 179 | ||||
| 2017-07-18 | 2017-07-14 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 37,1900 | 37 | 1 | 465 | ||||
| 2017-07-18 | 2017-07-14 | 4 | KESTER W CARL | BME | Performance Rights | D | 37,1900 | 36 | 1 | 1 070 | ||||
| 2017-07-18 | 2017-07-14 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 37,1900 | 139 | 5 | 2 058 | ||||
| 2017-07-18 | 2017-07-14 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 37,1900 | 92 | 3 | 1 019 | ||||
| 2017-07-18 | 2017-07-14 | 4 | Harris Jerrold B | BME | Performance Rights | D | 37,1900 | 150 | 6 | 2 184 | ||||
| 2017-07-18 | 2017-07-14 | 4 | Castellano Michael J | BME | Performance Rights | D | 37,1900 | 83 | 3 | 1 255 | ||||
| 2017-04-17 | 2017-04-13 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 34,2100 | 40 | 1 | 421 | ||||
| 2017-04-17 | 2017-04-13 | 4 | KESTER W CARL | BME | Performance Rights | D | 34,2100 | 39 | 1 | 1 016 | ||||
| 2017-04-17 | 2017-04-13 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 34,2100 | 151 | 5 | 1 886 | ||||
| 2017-04-17 | 2017-04-13 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 34,2100 | 60 | 2 | 122 | ||||
| 2017-04-17 | 2017-04-13 | 4 | Harris Jerrold B | BME | Performance Rights | D | 34,2100 | 163 | 6 | 1 999 | ||||
| 2017-04-17 | 2017-04-13 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 34,2100 | 100 | 3 | 912 | ||||
| 2017-04-17 | 2017-04-13 | 4 | Castellano Michael J | BME | Performance Rights | D | 34,2100 | 90 | 3 | 1 152 | ||||
| 2017-03-27 | 2017-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | 33,1200 | 4 062 | 135 | 4 062 | ||||
| 2017-01-18 | 2017-01-13 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 33,6500 | 101 | 3 | 798 | ||||
| 2017-01-18 | 2017-01-13 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 33,6500 | 153 | 5 | 1 705 | ||||
| 2017-01-18 | 2017-01-13 | 4 | KESTER W CARL | BME | Performance Rights | D | 33,6500 | 39 | 1 | 961 | ||||
| 2017-01-18 | 2017-01-13 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 33,6500 | 41 | 1 | 374 | ||||
| 2017-01-18 | 2017-01-13 | 4 | Castellano Michael J | BME | Performance Rights | D | 33,6500 | 91 | 3 | 1 044 | ||||
| 2017-01-18 | 2017-01-13 | 4 | Harris Jerrold B | BME | Performance Rights | D | 33,6500 | 166 | 6 | 1 804 | ||||
| 2017-01-18 | 2017-01-13 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 33,6500 | 61 | 2 | 61 | ||||
| 2016-10-18 | 2016-10-14 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 33,4300 | 41 | 1 | 672 | ||||
| 2016-10-18 | 2016-10-14 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 33,4300 | 154 | 5 | 1 495 | ||||
| 2016-10-18 | 2016-10-14 | 4 | KESTER W CARL | BME | Performance Rights | D | 33,4300 | 91 | 3 | 888 | ||||
| 2016-10-18 | 2016-10-14 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 33,4300 | 20 | 1 | 321 | ||||
| 2016-10-18 | 2016-10-14 | 4 | Castellano Michael J | BME | Performance Rights | D | 33,4300 | 92 | 3 | 918 | ||||
| 2016-10-18 | 2016-10-14 | 4 | Harris Jerrold B | BME | Performance Rights | D | 33,4300 | 167 | 6 | 1 579 | ||||
| 2016-07-19 | 2016-07-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 35,4800 | 19 | 1 | 296 | ||||
| 2016-07-19 | 2016-07-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 35,4800 | 145 | 5 | 1 319 | ||||
| 2016-07-19 | 2016-07-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 35,4800 | 37 | 1 | 620 | ||||
| 2016-07-19 | 2016-07-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 35,4800 | 85 | 3 | 784 | ||||
| 2016-07-19 | 2016-07-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 35,4800 | 86 | 3 | 812 | ||||
| 2016-07-19 | 2016-07-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 35,4800 | 157 | 6 | 1 389 | ||||
| 2016-04-19 | 2016-04-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 36,7600 | 37 | 1 | 574 | ||||
| 2016-04-19 | 2016-04-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 36,7600 | 19 | 1 | 272 | ||||
| 2016-04-19 | 2016-04-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 36,7600 | 140 | 5 | 1 154 | ||||
| 2016-04-19 | 2016-04-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 36,7600 | 83 | 3 | 687 | ||||
| 2016-04-19 | 2016-04-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 36,7600 | 83 | 3 | 714 | ||||
| 2016-04-19 | 2016-04-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 36,7600 | 151 | 6 | 1 212 | ||||
| 2016-01-20 | 2016-01-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 37,0400 | 83 | 3 | 620 | ||||
| 2016-01-20 | 2016-01-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 37,0400 | 150 | 6 | 1 043 | ||||
| 2016-01-20 | 2016-01-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 37,0400 | 41 | 2 | 527 | ||||
| 2016-01-20 | 2016-01-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 37,0400 | 139 | 5 | 997 | ||||
| 2016-01-20 | 2016-01-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 37,0400 | 82 | 3 | 594 | ||||
| 2016-01-20 | 2016-01-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 37,0400 | 20 | 1 | 249 | ||||
| 2015-10-19 | 2015-10-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 40,2500 | 138 | 6 | 879 | ||||
| 2015-10-19 | 2015-10-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 40,2500 | 128 | 5 | 846 | ||||
| 2015-10-19 | 2015-10-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 40,2500 | 76 | 3 | 529 | ||||
| 2015-10-19 | 2015-10-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 40,2500 | 72 | 3 | 484 | ||||
| 2015-10-19 | 2015-10-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 40,2500 | 127 | 5 | 882 | ||||
| 2015-10-19 | 2015-10-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 40,2500 | 66 | 3 | 505 | ||||
| 2015-10-19 | 2015-10-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 40,2500 | 34 | 1 | 226 | ||||
| 2015-10-19 | 2015-10-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 40,2500 | 14 | 1 | 142 | ||||
| 2015-10-19 | 2015-10-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 40,2500 | 72 | 3 | 479 | ||||
| 2015-07-16 | 2015-07-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 44,8800 | 61 | 3 | 447 | ||||
| 2015-07-16 | 2015-07-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 44,8800 | 99 | 4 | 732 | ||||
| 2015-07-16 | 2015-07-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 44,8800 | 96 | 4 | 708 | ||||
| 2015-07-16 | 2015-07-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 44,8800 | 11 | 0 | 126 | ||||
| 2015-07-16 | 2015-07-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 44,8800 | 55 | 2 | 402 | ||||
| 2015-07-16 | 2015-07-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 44,8800 | 55 | 2 | 407 | ||||
| 2015-07-16 | 2015-07-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 44,8800 | 101 | 5 | 745 | ||||
| 2015-07-16 | 2015-07-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 44,8800 | 59 | 3 | 434 | ||||
| 2015-07-16 | 2015-07-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 44,8800 | 26 | 1 | 190 | ||||
| 2015-04-17 | 2015-04-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 43,1400 | 11 | 0 | 114 | ||||
| 2015-04-17 | 2015-04-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 43,1400 | 105 | 5 | 637 | ||||
| 2015-04-17 | 2015-04-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 43,1400 | 27 | 1 | 162 | ||||
| 2015-04-17 | 2015-04-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 43,1400 | 57 | 2 | 348 | ||||
| 2015-04-17 | 2015-04-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 43,1400 | 100 | 4 | 606 | ||||
| 2015-04-17 | 2015-04-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 43,1400 | 57 | 2 | 344 | ||||
| 2015-04-17 | 2015-04-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 43,1400 | 61 | 3 | 371 | ||||
| 2015-04-17 | 2015-04-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 43,1400 | 63 | 3 | 382 | ||||
| 2015-04-17 | 2015-04-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 43,1400 | 103 | 4 | 625 | ||||
| 2015-01-20 | 2015-01-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 40,5000 | 106 | 4 | 501 | ||||
| 2015-01-20 | 2015-01-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 40,5000 | 110 | 4 | 516 | ||||
| 2015-01-20 | 2015-01-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 40,5000 | 67 | 3 | 315 | ||||
| 2015-01-20 | 2015-01-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 40,5000 | 61 | 2 | 287 | ||||
| 2015-01-20 | 2015-01-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 40,5000 | 112 | 5 | 526 | ||||
| 2015-01-20 | 2015-01-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 40,5000 | 65 | 3 | 306 | ||||
| 2015-01-20 | 2015-01-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 40,5000 | 29 | 1 | 134 | ||||
| 2015-01-20 | 2015-01-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 40,5000 | 12 | 0 | 102 | ||||
| 2015-01-20 | 2015-01-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 40,5000 | 60 | 2 | 284 | ||||
| 2014-12-11 | 2014-12-09 | 4 | GABBAY HENRY | BME | Common Stock | D | 42,1916 | −650 | −27 | 0 | ||||
| 2014-12-09 | 2014-12-05 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 42,9500 | 1 | 0 | 210 | ||||
| 2014-12-09 | 2014-12-05 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 42,9500 | 4 | 0 | 370 | ||||
| 2014-12-09 | 2014-12-05 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 42,9500 | 1 | 0 | 212 | ||||
| 2014-12-09 | 2014-12-05 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 42,9500 | 1 | 0 | 84 | ||||
| 2014-10-17 | 2014-10-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 36,0100 | 27 | 1 | 82 | ||||
| 2014-10-17 | 2014-10-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 36,0100 | 126 | 5 | 384 | ||||
| 2014-10-17 | 2014-10-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 36,0100 | 32 | 1 | 98 | ||||
| 2014-10-17 | 2014-10-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 36,0100 | 69 | 2 | 210 | ||||
| 2014-10-17 | 2014-10-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 36,0100 | 119 | 4 | 363 | ||||
| 2014-10-17 | 2014-10-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 36,0100 | 68 | 2 | 207 | ||||
| 2014-10-17 | 2014-10-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 36,0100 | 73 | 3 | 224 | ||||
| 2014-10-17 | 2014-10-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 36,0100 | 76 | 3 | 231 | ||||
| 2014-10-17 | 2014-10-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 36,0100 | 124 | 4 | 377 | ||||
| 2014-07-17 | 2014-07-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 36,4000 | 27 | 1 | 55 | ||||
| 2014-07-17 | 2014-07-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 36,4000 | 125 | 5 | 257 | ||||
| 2014-07-17 | 2014-07-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 36,4000 | 118 | 4 | 243 | ||||
| 2014-07-17 | 2014-07-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 36,4000 | 32 | 1 | 65 | ||||
| 2014-07-17 | 2014-07-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 36,4000 | 67 | 2 | 138 | ||||
| 2014-07-17 | 2014-07-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 36,4000 | 68 | 2 | 140 | ||||
| 2014-07-17 | 2014-07-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 36,4000 | 73 | 3 | 150 | ||||
| 2014-07-17 | 2014-07-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 36,4000 | 75 | 3 | 154 | ||||
| 2014-07-17 | 2014-07-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 36,4000 | 123 | 4 | 252 | ||||
| 2014-04-17 | 2014-04-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 34,9100 | 123 | 4 | 123 | ||||
| 2014-04-17 | 2014-04-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 34,9100 | 70 | 2 | 70 | ||||
| 2014-04-17 | 2014-04-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 34,9100 | 76 | 3 | 76 | ||||
| 2014-04-17 | 2014-04-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 34,9100 | 130 | 5 | 130 | ||||
| 2014-04-17 | 2014-04-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 34,9100 | 28 | 1 | 28 | ||||
| 2014-04-17 | 2014-04-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 34,9100 | 71 | 2 | 71 | ||||
| 2014-04-17 | 2014-04-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 34,9100 | 33 | 1 | 33 | ||||
| 2014-04-17 | 2014-04-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 34,9100 | 78 | 3 | 78 | ||||
| 2014-04-17 | 2014-04-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 34,9100 | 128 | 4 | 128 | ||||
| 2012-09-19 | 2012-09-19 | 4 | Castellano Michael J | BME | Common Stock | D | 27,7099 | 400 | 11 | 400 | ||||
| 2012-09-14 | 3 | Accettella Christopher | BME | Common Stock | D | 304 | ||||||||
| 2005-12-16 | 2005-12-06 | 4/A | McClements Kyle | BME | Common Stock | D | 25,3600 | 100 | 3 | 100 | ||||
| 2005-12-08 | 2005-12-06 | 4 | McClements Kyle | BME | Common Stock | D | 25,3600 | 100 | 3 | 100 |
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)
